Ubs Group Ag Xilio Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding XLO
# of Institutions
34Shares Held
14MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$4.29 Million0.65% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3MShares$2.82 Million0.08% of portfolio
-
Morgan Stanley New York, NY1.52MShares$1.43 Million0.0% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.35 Million16.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$848,3790.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $25.8M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...